The two designed compounds, dubbed NG1 and DN1, effectively treated N. gonorrhoeae and S. aureus respectively in preclinical models.

Dementia-like protein clumps found in pancreatic precancer mouse cells point to autophagy defects, offering cancer ...

Researchers demonstrate that an engineered antibody improves a class of drugs that has struggled to make good on its early promise.

Schrödinger has halted development of its cancer-fighting candidate SGR-2921 after two patients treated with the CDC7 inhibitor died in a Phase I trial.

Peptidoglycan hydrolases killed living bacteria, opening the door for further research into the interplay between archaea and bacteria.